Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 6/20 | 0.51 |
| ▸ | HPGDS | O60760 | 6/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | HTR1B | P28222 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23928546 | 0.76 | GAA (0.49) | HPGDSGAAUSP2CYP3A4POLB | |
| SCHEMBL23928580 | 0.76 | GAA (0.49) | HPGDSGAAUSP2CYP3A4POLB | |
| SCHEMBL23928553 | 0.70 | GAA (0.57) | HPGDSGAAUSP2CYP3A4POLB | |
| SCHEMBL14590544 | 0.70 | KMT2A (0.57) | GAAUSP2CYP3A4HIF1ASMN1; SMN2 | |
| SCHEMBL5655889 | 0.68 | KMT2A (0.63) | HPGDSGAAUSP2CYP3A4HIF1A | |
| SCHEMBL1664653 | 0.68 | HPGDS (0.51) | HPGDS | |
| SCHEMBL5658689 | 0.68 | USP2 (0.78) | HPGDSGAAUSP2CYP3A4HIF1A | |
| SCHEMBL23928512 | 0.67 | GAA (0.53) | HPGDSGAAUSP2CYP3A4HIF1A | |
| SCHEMBL22111258 | 0.67 | GAA (0.48) | HPGDSGAAUSP2CYP3A4POLB | |
| SCHEMBL1663209 | 0.66 | HPGDS (0.51) | HPGDSSMN1; SMN2ALDH1A1HTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548875-B2 | Inhibitor compounds for male contraception | UNIVERSITY OF WASHINGTON (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210332030-A1 | INHIBITOR COMPOUNDS FOR MALE CONTRACEPTION | UNIVERSITY OF WASHINGTON (US) | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210332030-A1 | INHIBITOR COMPOUNDS FOR MALE CONTRACEPTION | ALDH1A1, ALDH3A1, ALDH16A1 | NPY2R 3693/4885HPGDS 491/4885GAA 3740/4885 |
| US-11548875-B2 | Inhibitor compounds for male contraception | ALDH1A1, ALDH3A1, ALDH16A1 | NPY2R 3693/4885HPGDS 491/4885GAA 3740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.